However, Launch of New Agents Will Drive Growth in the Long-Acting Beta- Agonist/Inhaled Corticosteroid Class, According to a New Report from Decision Resources WALTHAM, Mass., May 19
WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that increased product competition, generic and/or branded-
generic price erosion, and cost consciousness will constrain growth in the
asthma drug market as sales will decline from $10.9 billion in 2007 to $10.1
billion in 2017 in the world's major pharmaceutical markets.
The new Pharmacor report entitled Asthma finds that although sales will
decline over the next decade in the United States, France, Germany, Italy,
Spain, United Kingdom and Japan, the launch of several new long-acting beta-
agonist/inhaled corticosteroid (LABA/ICS) combinations will drive growth in
this class. However, none of five new LABA/ICS therapies that are set to
launch by 2017 will overtake the current market leader in this class-
GlaxoSmithKline's Advair/Seretide/Adoair, owing to its well-established
patient share.
The report also finds that although the asthma market is saturated with
many safe and effective drugs, pharmaceutical companies continue to develop
new therapies to maximize their earning potential in this lucrative market.
"Asthma therapies that are emerging over the next ten years in the U.S.,
European, and/or Japanese markets that offer improved convenience will capture
market share but will still not surpass sales of Advair/Seretide/Adoair," said
Amy Whiting, Ph.D. analyst at Decision Resources. "Other key players will rely
on competitive pricing, incremental gains in safety, or improved efficacy to
differentiate themselves from competitors."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services, and consulting designed to help
clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or
registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources, Inc.
